CompletedPhase 3

Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke

Iran90 participantsStarted 2021-08-08

Plain-language summary

This is a randomized, controlled, active comparator arm, outcome assessor blind, parallel group design on 90 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is assess the efficacy of ticagrelor plus aspirin in reduce of minor non-cardioembolic ischemic stroke or high risk TIA recurrence during first 3 months.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * signing inform consent, * recent ischemic stroke within 24 h, * diagnosed by brain CT or MRI mild stroke with NIHSS =\<8 and no evidence of large infarct in brain imaging * high risk TIA with ABCD \>4, * no cardioembolic source such as low E/F, MS, AF ,... * no specific etiology such as dissection, vasculitis, ... * no carotid stenosis \> 50 % in side of involvement Exclusion Criteria: * history of hypersensitivity to consumptive drug * any indication for anticoagulant therapy * acute phase treatment with intravenous thrombolysis or thrombectomy * any contraindication for consumptive drug * history of intracranial hemorrhage * history of GI bleeding during past 6 m * candidate for endarterectomy * history of coagulopathy * active hemorrhagic diathesis during randomization

What they're measuring

ischemic stroke recurrence

Timeframe: first 3 months after first event

Trial details

NCT IDNCT04738097

SponsorMazandaran University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-10-10

View on ClinicalTrials.gov More Ischemic Stroke trials